FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of April 2026
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Total Voting Rights and Admission of Shares
1 April 2026
Total Voting Rights and Notification of Admission of Further
Securities to Trading (PRM 1.6.4R)
Total Voting Rights
The following notification is made in accordance with the UK
Financial Conduct Authority's Disclosure and Transparency Rule
5.6.1. As at 31 March 2026 the issued share capital of AstraZeneca
PLC with voting rights is 1,550,980,823 ordinary shares of US$0.25.
No shares are held in Treasury. Therefore, the total number of
voting rights in AstraZeneca PLC is 1,550,980,823.
The above figure for the total number of voting rights may be used
by shareholders as the denominator for the calculations by which
they will determine if they are required to notify their interest
in, or a change to their interest in, AstraZeneca PLC under the UK
Financial Conduct Authority's Disclosure and Transparency
Rules.
Notification of Admission of Further Securities to Trading (PRM
1.6.4R)
The following notification is made in accordance with The Public
Offers and Admissions to Trading Regulations 2024 (POATRs) PRM
1.6.4R.
|
1
|
Details of the issuer
|
|
|
a)
|
Name
|
AstraZeneca PLC
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
2
|
Details of the transferable securities admitted to
trading
|
|
|
a)
|
Name, type and identification code
|
Ordinary Shares of $0.25 each
ISIN: GB0009895292
|
|
b)
|
Regulated market
|
London Stock Exchange - Main Market
|
|
c)
|
Number of further securities issued and admitted
|
491
|
|
d)
|
Total number of securities in issue following
admission
|
1,550,980,823
|
|
e)
|
Fungibility
|
Fully fungible with existing Ordinary Shares
|
|
3
|
Admission details
|
|
|
a)
|
Date of admission
|
Issued between 20 March 2026 to 31 March 2026 (admitted under a
block admission dated 29
January 2021)
|
|
b)
|
Prospectus information
|
Prospectus: N/A
Supplementary: N/A
Company's webpage: https://www.astrazeneca.com
|
|
c)
|
Coverage of notification
|
Admission of shares under the Company's employee share schemes from
20 March 2026 up to 31 March 2026, admitted to trading on the Main
Market of the London Stock Exchange under the Company's existing
block admission of shares dated 29 January 2021.
|
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Matthew Bowden
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
01 April 2026
|
|
By: /s/
Matthew Bowden
|
|
|
Name:
Matthew Bowden
|
|
|
Title:
Company Secretary
|